AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25765705
Drug: RM1 (≥3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RM1 (≥3 days and/or nights of cough, wheeze, and/or medicine use) documented by parental diaries at 12 months corrected age
Trial: 25765705
Drug: RM2 (≥4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RM2 (≥4 days and/or nights of cough, wheeze, and/or respiratory medicine use) documented by parental diaries at 12 months corrected age
Trial: 16600508
Drug: Oxycodone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (15 mg)
Trial: 31391001
Drug: Control (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.9% saline infusion)
Trial: 12208482
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus pravastatin (40 mg/day)
Trial: 10596735
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (150-400 mg/day)
Trial: 10596735
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR and Sertraline
Trial: 19434360
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day omeprazole
Trial: 6134979
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day omeprazole
Trial: 27184789
Drug: Inpatient psychodynamic
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient psychodynamic treatment
Trial: 30986750
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy at discharge
Trial: 24576541
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin therapy at discharge
Trial: 22733948
Drug: One-dose TEA
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose TEA group (10 mg/kg intra-operatively)
Trial: 22733948
Drug: Two-dose TEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose TEA group (10 mg/kg pre-operatively and intra-operatively)
Trial: 18274163
Drug: Weekly nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly nutrition education based on the nutrition triangle concept of UNICEF for 6 months
Trial: 14530690
Drug: Degassed aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degassed aqueous solution made of 40 ml of water and 10 ml of dimethicone emulsion (1 ml/100 mg)
Trial: 1406817
Drug: Tacrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (10 or 20 mg four times a day)
Trial: 6428371
Drug: Haloperidol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1.0 to 6.0 mg/day)
Trial: 6428371
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (500 to 2,000 mg/day)
Trial: 24641941
Drug: Olokizumab (OKZ)
RxNorm normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olokizumab (OKZ) 60 mg
Trial: 24641941
Drug: Olokizumab (OKZ)
RxNorm normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olokizumab (OKZ) 120 mg
Trial: 24641941
Drug: Olokizumab (OKZ)
RxNorm normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olokizumab (OKZ) 240 mg
Trial: 24641941
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 8 mg/kg Q4W
Trial: 22522225
Drug: Lopinavir-ritonavir (400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (400mg and 100mg respectively) administered after a moderate-fat breakfast
Trial: 22522225
Drug: Coprandial administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coprandial administration of formulations
Trial: 24636673
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus extended-release dipyridamole
Trial: 10613628
Drug: Graded workload
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded workload treadmill protocol (G-test; 2 mph; 0% grade, increasing 2% every 2 min)
Trial: 10613628
Drug: Graded workload
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded workload treadmill protocol (G-test)
Trial: 2015162
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg three times daily for 10 days)
Trial: 7159883
Drug: procainamide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: procainamide 1.0 g t.i.d.
Trial: 7159883
Drug: disopyramide 150
RxNorm normalized name: disopyramide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: disopyramide 150 mg t.i.d.
Trial: 29108096
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Substance Abuse-Domestic Violence (SADV)
Trial: 25185754
Drug: 6:1‐OM3 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6:1‐OM3 (4 g/day)
Trial: 25185754
Drug: 6:1‐OM3 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6:1‐OM3 (4 g/day) in hypertriglyceridemic subjects
Trial: 17594926
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg once daily
Trial: 16275811
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus a 15-session group cognitive therapy prevention program (n = 45)
Trial: 2909288
Drug: Furosemide 20
RxNorm normalized name: furosemide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 20 mg/m2 1 hour before CDDP administration
Trial: 2909288
Drug: No diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diuretic drug (Control)
Trial: 31286728
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding (at specific acupoints), once every two weeks, six times as a course of treatment, until 12 weeks into pregnancy.
Trial: 31286728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with intramuscular injection of progesterone (40 mg) once every day.
Trial: 28111716
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab (250 mg/m2 given twice 1 week apart per cycle)
Trial: 28111716
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with low-dose rituximab
Trial: 28111716
Drug: One cycle
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of low-dose rituximab
Trial: 28111716
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or more cycles of low-dose rituximab
Trial: 24723493
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab
Trial: 25988270
Drug: Real Auricular
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real Auricular Point Acupressure (APA) treatment
Trial: 25988270
Drug: Sham Auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Auricular Point Acupressure treatment
Trial: 24120678
Drug: 2+1-dose group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2+1-dose group (PCV7 at 2, 4, and 11 months)
Trial: 24120678
Drug: 2-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose group (PCV7 at 2 and 4 months)
Trial: 24120678
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose at 24 months
Trial: 21611896
Drug: Tongjiang granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongjiang granule (TJG) 10 g and mosapride citrate dummy 5 mg three times a day
Trial: 21611896
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate 5 mg and TJG dummy 10 g three times a day
Trial: 16687481
Drug: Salbutamol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (12 mg/day for four weeks)
Trial: 16086881
Drug: China-made tropisetron
RxNorm normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: China-made tropisetron hydrochloride (5 mg, intravenously)
Trial: 10608948
Drug: Liquid nutrition
RxNorm normalized name: Liquid Nutrition Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid nutrition supplement (six 235‐mL cans weekly)
Trial: 2125513
Drug: Neutron treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron treatment
Trial: 2125513
Drug: Photon treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon treatment
Trial: 295576
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of L-asparaginase
Trial: 295576
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of L-asparaginase
Trial: 24667715
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (EndoTAG‐1 22 mg/m(2) + paclitaxel 70 mg/m(2))
Trial: 24667715
Drug: EndoTAG‐1 (2×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoTAG‐1 (2× 44 mg/m(2))
Trial: 24667715
Drug: Paclitaxel (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (90 mg/m(2))
Trial: 21756154
Drug: Combination formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination formulation (5% hexane extract of Curcuma aeruginosa + 5% minoxidil)
Trial: 16837516
Drug: Activating, structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activating, structured treatment by social workers
Trial: 12539884
Drug: Eucarbon (charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucarbon (charcoal tablets)
Trial: 9424977
Drug: Famciclovir, 500
RxNorm normalized name: Famciclovir, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir, 500 mg orally twice daily for 8 weeks
Trial: 7656833
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high dose DDP (Cisplatin)
Trial: 7656833
Drug: Fractionated low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated low doses DDP (Cisplatin)
Trial: 2569959
Drug: Betaxolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol (20 mg/day)
Trial: 2569959
Drug: Minoxidil (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil (5.5 mg/day, added at week 6 if SDAP > 95 mm Hg)
Trial: 27894198
Drug: 27 mg
RxNorm normalized name: aspirin 227 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27 mg elemental iron daily (group I)
Trial: 27894198
Drug: 54 mg
RxNorm normalized name: aspirin 454 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54 mg elemental iron daily (group II)
Trial: 25301007
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care interventions developed by the clinical pharmacist in collaboration with the physician
Trial: 25301007
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care interventions
Trial: 24189342
Drug: Fluoxetine, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine, 40 mg per day for 3 weeks
Trial: 15468944
Drug: Iodine concentration
RxNorm normalized name: iodine Topical Solution [QuarterMate Concentrate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine concentration of 370 mg/mL (Group B)
Trial: 15468944
Drug: Iodine concentration
RxNorm normalized name: iodine Topical Solution [QuarterMate Concentrate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine concentration of 300 mg/mL (Group A)
Trial: 9630813
Drug: Salofalk (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salofalk (500 mg)
Trial: 9630813
Drug: Pentasa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa (500 mg)
Trial: 8310405
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (1 gm cephalothin intravenously 30 minutes before the procedure and 500 mg cephalexin orally every 6 hours for 3 days afterward)
Trial: 21703048
Drug: Tadalafil plus
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil plus Vacuum Erection Device (VED), 10 minutes unbanded per day for at least 5 days weekly
Trial: 16093403
Drug: Powdered fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered fermented milk with L. helveticus CM4 (12 g daily for 4 weeks)
Trial: 16093403
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 g daily for 4 weeks)
Trial: 10442275
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide at a dose of 2,400 micrograms daily
Trial: 10442275
Drug: Systemic corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroid (standard adjunctive therapy)
Trial: 7792016
Drug: Hyperuricemia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperuricemia group with triglycerides > 200 mg/dl
Trial: 2217030
Drug: Lornoxicam 4
RxNorm normalized name: lornoxicam 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 4 mg twice daily
Trial: 24434887
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy exercise program (3 months)
Trial: 20933640
Drug: Sequential multidetector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential multidetector CT (MDCT)
Trial: 1541613
Drug: Single 800-centigray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 800-centigray dose of limited-field radiation
Trial: 1541613
Drug: 1000 centigray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 centigray of limited-field radiation in divided doses
Trial: 3993426
Drug: Iohexol 350
RxNorm normalized name: iohexol 350 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol 350 mg I/ml, 500 mg I/kg body weight
Trial: 3993426
Drug: Metrizoate 350
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrizoate 350 mg I/ml, 500 mg I/kg body weight
Trial: 29935583
Drug: Dexmedetomidine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.5 ng ml‐1)
Trial: 29935583
Drug: Propofol (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.7 μg ml‐1)
Trial: 29935583
Drug: S-ketamine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (0.75 μg ml‐1)
Trial: 27142970
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (IV group)
Trial: 24262818
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) plus usual care
Trial: 18062586
Drug: Hypocalcaemia during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocalcaemia during treatment
Trial: 8918628
Drug: Non-Epo treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-Epo treatment
Trial: 8918628
Drug: Epo treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epo treatment
Trial: 1323587
Drug: MK-571 (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (450 mg total dose)
Trial: 1323587
Drug: MK-571 (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (37.5 mg total dose)
Trial: 6381167
Drug: Ibuprofen 1600
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1600 mg daily
Trial: 6381167
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg daily
Trial: 28965385
Drug: Modified Jujing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Jujing No.2 Decoction (1 dose a day, bid)
Trial: 28965385
Drug: Danshen Tablets
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen Tablets (4 tablets once, tid) plus Liu Wei Di Huang Wan (8 pills once, tid)
Trial: 23743404
Drug: Sapropterin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin (10 mg/kg)
Trial: 19536889
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (CAB) with LHRH-A plus bicalutamide 80 mg
Trial: 19536889
Drug: LHRH-A monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH-A monotherapy
Trial: 11770031
Drug: Steroid (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (250 mg of prednisolone)
Trial: 11770031
Drug: Heparin coating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin coating of the artificial surface (Bioline)
Trial: 7946230
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication (control group)
Trial: 2829953
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Fenoterol and Salbutamol)
Trial: 12472583
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of micronized 17beta‐oestradiol (E2)
Trial: 12472583
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of micronized 17beta‐oestradiol + 10 mg dydrogesterone (E2 + D)
Trial: 9506490
Drug: Triamcinolone diacetate,
RxNorm normalized name: triamcinolone diacetate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone diacetate, 40 mg intramuscular (i.m.)
Trial: 9506490
Drug: Prednisone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 40 mg/day orally for 5 days
Trial: 7922010
Drug: Buffy coat
RxNorm normalized name: Leucocyte buffy coat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffy coat preparation method with yield-enhancing change
Trial: 7922010
Drug: Allogeneic marrow
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic marrow infusion
Trial: 3049173
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% bifonazole cream
Trial: 11288030
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone (NAL) infusion (1.6 mg/h for 2.5 hours) during GHRH testing
Trial: 30408100
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tests of ET function
Trial: 22469877
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy program (25 mins, twice a day, five times a week, for 4 weeks)
Trial: 22469877
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy program
Trial: 17567301
Drug: Adapalene gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene gel, 0.1% once daily (QD)
Trial: 17567301
Drug: Adapalene gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene gel, 0.1% every other day (QoD)
Trial: 15692069
Drug: ABO-compatible platelets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABO-compatible platelets, stored for 48 hours or less, large doses of platelets
Trial: 15692069
Drug: Filtered apheresis
RxNorm normalized name: FILTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtered apheresis platelets, increased dose of platelets transfused
Trial: 15692069
Drug: Heparin administration,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration, fever, bleeding, increasing number of platelet transfusions, increasing weight, at least 2 pregnancies, male gender